Clinical trials: Prospective Memory
Memory Disorder, Retention Disorder, Cognitive
Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems
In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.
- Conditions
- Memory Disorder, Retention Disorder, Cognitive, Subjective Cognitive Impairment, Memory, Concentration or Attention Problems
- Trial name
- NCT01261741
- Testing
- Memantine
- Where
- 14 sites in Germany, United Kingdom
- Volunteers
- 299 people
- Sponsor
- Merz Pharmaceuticals GmbH
Memory Deficit
Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders
The purpose of this study is to evaluate the efficacy and safety of two different drugs in the treatment of patients diagnosed with memory difficulties and a decline in cognitive function.
- Trial name
- NCT01637168
- Testing
- Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin, Ginkgo Biloba (Tebonin®)
- Where
- Brazil
- Sponsor
- EMS
Healthy Participants, Healthy Population
Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants
The present study aims to assess the safety and feasibility of repeated transcranial alternating current stimulation (tACS) by the Miamind Neurostimulator in a cohort of healthy participants.
- Trial name
- MindStim (NCT05999916)
- Testing
- Personalized Miamind Neurostimulator
- Where
- Switzerland
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bottneuro AG
Cognitive Impairment, Memory Complaint
Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Cognitive Impairment, Memory Complaint, Clinical Investigation in Memory Centers
- Trial name
- DIALOG (NCT02221661)
- Volunteers
- 606 people
- Sponsor
- Diaxonhit
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Memory, Learning
Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L
The purpose of this study is to determine the efficacy and safety of REMEMBER-fX (HT1001, an extract of Panax quinquefolius) in a human sample using standard clinical neuropsychological instruments and side effects rating scales.
- Conditions
- Memory, Learning, Attention, Cognition
- Trial name
- REMEMBER-fX (NCT00527969)
- Testing
- HT1001 extract of Panax quinquefolius L
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CV Technologies
Terminal Illness, End-of-Life Care
Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence
Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power…
- Conditions
- Terminal Illness, End-of-Life Care, Death, Brain Death
- Trial name
- NeuroCogPresv (NCT07477028)
- Volunteers
- 20 people
- Sponsor
- Noah Tech, Corp.
Dementia, Mild Cognitive Impairment
Prospective Research in Memory Clinics (PRIME)
The purpose of the PRIME Study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia.
- Trial name
- NCT00297271
- Testing
- Current treatment practice of each participating physician
- Where
- 9 sites in Australia
- Volunteers
- 970 people
- Sponsor
- Janssen-Cilag Pty Ltd